Featured publications
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
November 2, 2023 | The New England Journal of Medicine
Multi-omic single cell sequencing: Overview and opportunities for kidney disease therapeutic development
April 5, 2023 | Frontiers in Molecular Biosciences
Quantifying the nativeness of antibody sequences using long short-term memory networks
December 31, 2019 | Protein Engineering, Design, and Selection
A chemoselective strategy for late-stage functionalization of complex small molecules with polypeptides and proteins
November 5, 2018 | Nature Chemistry
Antibody-Bactericidal Macrocyclic Peptide Conjugates to Target Gram Negative Bacteria
September 14, 2018 | Chembiochem: A European Journal of Chemical Biology
Extending human IgG half-life using structure-guided design.
May 3, 2018 | mAbs
Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.
February 9, 2018 | PLoS Neglected Tropical Diseases
Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates.
May 18, 2017 | Antiviral Research
A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.
October 14, 2016 | https://pubmed.ncbi.nlm.nih.gov/27751627/
The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome.
March 25, 2016 | Antimicrobial Agents and Chemotherapy
Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks
March 5, 2016 | EBioMedicine
A broadly neutralizing human monoclonal antibody is effective against H7N9.
August 7, 2015 | PNAS
Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope.
July 30, 2015 | Cell
